Vitex (Chasteberry): PMS Evidence, Extracts, and Label Guide

Vitex supplements are made from Vitex agnus-castus, a shrub also called chaste tree. The relevant plant part on current European and Canadian monographs is the fruit. A label that states only “Vitex complex” leaves both botanical identity and preparation less clear. ^{2, 3}

Vitex does not supply progesterone or estrogen and should not be treated as hormone replacement. Its mechanism is not fully established. Dopaminergic and prolactin-related effects are discussed in the scientific and regulatory literature, but a supplement label cannot show that a person’s hormone level will change in a specific direction.

This distinction matters because “hormone balance” can make one herb sound like a universal answer for PMS, fertility, acne, irregular cycles, and menopause. Those are different claims with different evidence, and the label alone cannot diagnose why symptoms occur.

A 2017 review found an encouraging pooled effect for PMS, but most trials had a high risk of bias, heterogeneity was very high, and publication bias was possible. The authors warned that the combined result probably overestimated the true effect. ⁵

Preparation quality was a central problem, not a minor reporting detail. A 2019 meta-analysis found 21 clinical trials, but only three placebo-controlled studies involving 520 participants sufficiently characterized the Vitex products for inclusion. Those studies tested the specific extracts Ze 440 and BNO 1095, not generic chasteberry powder or every product labeled “standardized.” ⁶

NCCIH therefore describes the current evidence conservatively: some research suggests a reduction in PMS symptoms such as breast pain or tenderness, but higher-quality evidence is still needed for a firm conclusion. ¹

A bigger number does not automatically mean a stronger or more evidence-aligned Vitex product. Milligrams of dried fruit, milligrams of concentrated extract, and a dried-fruit equivalent answer different label questions. The extraction ratio and solvent help identify how the extract was made. ^{2, 3}

The same principle applies to standardization. Agnuside or casticin wording can identify a declared marker specification, but a marker percentage alone does not prove that a product matches Ze 440, BNO 1095, or another clinically studied preparation.

For a deeper explanation of why powders and extracts should not be compared by name alone, see the guide to extracts and powders.

Start with the line that names the ingredient and plant part. Then separate extract mass from any stated fruit equivalent, read the full daily serving rather than one capsule, and check whether the preparation is disclosed outside a proprietary blend.

A clearly disclosed marker percentage can add useful preparation detail, but it cannot rescue a label that omits the individual Vitex amount, plant part, or serving context. Likewise, a branded extract name is useful only when the label identifies the actual ingredient and amount rather than relying on a front-label badge.

Vitex frequently appears with vitamin B6, magnesium, DIM, black cohosh, or other botanicals. Their presence does not prove synergy, and one ingredient’s clinical context should not be transferred to the complete formula without evidence for that formula.

Compare the amount per full daily serving, repeated ingredients, hormone-containing medicines or contraceptives, and whether each botanical has its own amount. A proprietary “female balance matrix” can hide which ingredient contributes most of the blend weight.

The EMA monograph includes a well-established-use preparation of 20 mg per day for a specific dry fruit extract with a DER of 6:1 to 12:1 and 60% ethanol as the extraction solvent. The same monograph includes other extract and fruit-powder preparations with very different masses. These are preparation-specific regulatory contexts, not a single conversion chart for retail supplements. ²

In a 162-participant dose study of the defined extract Ze 440, 20 mg performed better than placebo and 8 mg over three menstrual cycles. The 30 mg dose did not clearly outperform 20 mg. This is useful evidence that more milligrams are not automatically better, but it does not establish 20 mg as the right amount for a different extract. ⁷

Health Canada’s 2024 monograph lists 30 to 2,000 mg of dried fruit per day across dry fruit, powder, and specified non-standardized preparations. That broad licensing range should not be read as proof that every amount works equally, or as a personal dosing instruction. ³

NCCIH reports that chasteberry fruit extract has generally been well tolerated in short-term studies lasting up to three months. Commonly reported effects are usually mild and include nausea, stomach pain, diarrhea, headache, or itching. EMA also lists reported adverse effects including severe allergic reactions, rash or urticaria, dizziness, nausea, abdominal pain, acne, and menstrual disorders; their frequency is not known. Short trial duration is not evidence of established long-term safety. ^{1, 2}

Health Canada states that Vitex should not be used during pregnancy, breastfeeding, or while attempting to conceive unless a health care professional has been consulted. Its monograph also tells users of hormone-containing medicines, including progesterone preparations, oral contraceptives, and hormone replacement therapy, to ask a health professional before use. ^{3, 4}

The Australian TGA describes the evidence for an interaction with oral contraceptives as limited, but recognizes a potential interaction and advises people using contraceptive, hormonal, or dopaminergic medicines to consult a health professional before combined use. That is a precaution, not proof that every combination will fail or cause harm. ⁸

EMA additionally advises medical consultation for people with a history of pituitary disorders or estrogen-sensitive cancer and for those using dopamine agonists, dopamine antagonists, estrogens, or antiestrogens. It also notes that in prolactin-secreting pituitary tumors, agnus castus fruit may mask symptoms of the tumor. These are important medicine and clinical-context limits, not issues that can be cleared from a supplement label alone. ²